PSMA-SRT 试验 NCT03582774 更新：一项针对前列腺癌复发挽救性放疗的前列腺特异性膜抗原正电子发射断层扫描的随机 3 期影像学试验，旨在获得临床结局。
Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.
机构信息
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA; Institute of Urologic Oncology, University of California, Los Angeles, Los Angeles, CA, USA; Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
出版信息
Eur Urol Focus. 2021 Mar;7(2):238-240. doi: 10.1016/j.euf.2020.12.009. Epub 2020 Dec 30.
Abstract
The purpose of this randomized trial is to evaluate the success rate of salvage radiation therapy for recurrence of prostate cancer after radical prostatectomy, with and without planning based on prostate-specific membrane antigen positron emission tomography/computed tomography. Enrollment has been completed and patients are being followed for 5yr.
摘要
本随机试验旨在评估基于前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描的计划与否对根治性前列腺切除术后前列腺癌复发进行挽救性放疗的成功率。目前已完成入组，正在对患者进行 5 年随访。
相似文献
1
Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.
Eur Urol Focus. 2021 Mar;7(2):238-240. doi: 10.1016/j.euf.2020.12.009. Epub 2020 Dec 30.
2
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
Eur Urol. 2024 Jul;86(1):52-60. doi: 10.1016/j.eururo.2024.01.012. Epub 2024 Jan 29.
3
Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial.
World J Urol. 2021 Nov;39(11):4117-4125. doi: 10.1007/s00345-021-03735-0. Epub 2021 Jun 2.
4
Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
BJU Int. 2021 May;127 Suppl 1:23-29. doi: 10.1111/bju.15315.
5
Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy.
Int J Radiat Oncol Biol Phys. 2022 Aug 1;113(5):1015-1024. doi: 10.1016/j.ijrobp.2022.04.048. Epub 2022 Jun 3.
6
Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
BMC Cancer. 2022 Apr 15;22(1):416. doi: 10.1186/s12885-022-09493-5.
7
(68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
BJU Int. 2016 May;117(5):732-9. doi: 10.1111/bju.13397. Epub 2016 Jan 24.
8
Patterns of relapse as determined by Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment.
Strahlenther Onkol. 2018 Apr;194(4):303-310. doi: 10.1007/s00066-017-1231-9. Epub 2017 Nov 13.
9
F-fluciclovine PET-CT and Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30.
10
Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
Eur Urol Focus. 2021 Mar;7(2):472-478. doi: 10.1016/j.euf.2019.06.008. Epub 2019 Jun 18.
引用本文的文献
1
PET imaging utilization and trends in Germany: a comprehensive survey.
Eur J Nucl Med Mol Imaging. 2025 May 3. doi: 10.1007/s00259-025-07323-x.
2
Long-term outcomes of PSMA PET/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis.
Eur J Nucl Med Mol Imaging. 2025 Apr 5. doi: 10.1007/s00259-025-07255-6.
3
cfDNA fragmentation patterns correlate with tumor burden measured via PSMA PET/CT volumetric parameters in patients with biochemical recurrence of prostate cancer.
EJNMMI Res. 2024 Dec 18;14(1):124. doi: 10.1186/s13550-024-01170-x.
4
Development and Internal Validation of a Novel Nomogram Predicting the Outcome of Salvage Radiation Therapy for Biochemical Recurrence after Radical Prostatectomy in Patients without Metastases on Restaging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
Eur Urol Open Sci. 2024 Feb 6;61:37-43. doi: 10.1016/j.euros.2024.01.009. eCollection 2024 Mar.
5
Impact of PSMA PET on Prostate Cancer Management.
Curr Treat Options Oncol. 2024 Feb;25(2):191-205. doi: 10.1007/s11864-024-01181-9. Epub 2024 Jan 25.
6
Clinical practice in prostate PET imaging.
Ther Adv Med Oncol. 2023 Nov 22;15:17588359231213618. doi: 10.1177/17588359231213618. eCollection 2023.
7
Detection of Biochemically Recurrent Prostate Cancer with [F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen Parameters.
Tomography. 2023 Aug 15;9(4):1504-1514. doi: 10.3390/tomography9040120.
8
PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
Cancers (Basel). 2023 Mar 29;15(7):2027. doi: 10.3390/cancers15072027.
9
Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death.
J Clin Oncol. 2023 May 1;41(13):2428-2435. doi: 10.1200/JCO.22.02489. Epub 2023 Mar 1.
10
Ga-PSMA PET/CT-Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines.
J Nucl Med. 2023 Jun;64(6):902-909. doi: 10.2967/jnumed.122.265025. Epub 2023 Feb 9.
本文引用的文献
1
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data.
Lancet. 2020 Oct 31;396(10260):1422-1431. doi: 10.1016/S0140-6736(20)31952-8. Epub 2020 Sep 28.
2
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Lancet Oncol. 2019 Dec;20(12):1740-1749. doi: 10.1016/S1470-2045(19)30486-3. Epub 2019 Oct 16.
3
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096.
4
Randomized prospective phase III trial of Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
BMC Cancer. 2019 Jan 7;19(1):18. doi: 10.1186/s12885-018-5200-1.
5
The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer.
J Nucl Med. 2018 Apr;59(4):557-567. doi: 10.2967/jnumed.117.196444. Epub 2018 Jan 4.
6
Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.
J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.
7
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):361-8. doi: 10.1016/j.ijrobp.2009.02.006. Epub 2009 Apr 23.
Zotero 插件